IMBdx

IMBdx is a precision oncology company committed to advancing safe and accurate cancer diagnosis, monitoring, and screening. We have developed a minimally-invasive liquid biopsy technology that detects cancer and monitors its progression with just a single blood draw. Our AlphaLiquid® test provides comprehensive genomic profiling (CGP) of tumors, identifying key mutations and offering personalized treatment options, including matching therapies and relevant clinical trial opportunities. In addition to AlphaLiquid®, we offer CancerDetectTM, a minimal residual disease (MRD) test that detects trace amounts of cancer cells remaining after treatment, allowing for early relapse detection. We also provide CancerFindTM, a multi-cancer early detection (MCED) test that screens for multiple types of cancer at once, even in asymptomatic patients, enabling earlier and more effective intervention. Since beginning our research in 2014, our goal has been to make cancer diagnosis more accessible and affordable for patients worldwide. For more information, please visit www.imbdx.com/eng/ or contact us at support@imbdx.com.